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Abstract 59 
Context: The alpha-subunit of the stimulatory G-protein (Gαs) links numerous receptors to adenylyl 60 
cyclase. Gαs, encoded by GNAS, is expressed predominantly from the maternal allele in certain tissues. 61 
Thus, maternal heterozygous loss-of-function mutations cause hormonal resistance, as in 62 
pseudohypoparathyroidism type Ia, while somatic gain-of-function mutations cause hormone-63 
independent endocrine stimulation, as in McCune-Albright Syndrome.  64 
Objective: We here report two unrelated boys presenting with a new combination of clinical findings 65 
that suggest both gain and loss of Gαs function. 66 
Design, Setting: Clinical features were studied and sequencing of GNAS was performed. Signaling 67 
capacities of wild-type and mutant-Gαs were determined in the presence of different G protein-coupled 68 
receptors (GPCRs) under basal and agonist-stimulated conditions. 69 
Results: Both unrelated patients presented with unexplained hyponatremia in infancy, followed by 70 
severe early-onset gonadotrophin-independent precocious puberty and skeletal abnormalities. An 71 
identical heterozygous de novo variant (c.1136T>G; p.F376V) was found on the maternal GNAS allele, 72 
in both patients; this resulted in a clinical phenotype that differ from known Gαs-related diseases and 73 
suggested gain-of-function at the receptors for vasopressin (V2R) and lutropin (LHCGR), yet increased 74 
serum parathyroid hormone (PTH) concentrations indicative of impaired proximal tubular PTH1 75 
receptor (PTH1R) function. In vitro studies demonstrated that Gαs-F376V enhanced ligand-independent 76 
signaling at the PTH1R, LHCGR and V2R and, at the same time, blunted ligand-dependent responses. 77 
Structural homology modeling suggested mutation-induced modifications at the C-terminal α5-helix of 78 
Gαs that are relevant for interaction with GPCRs and signal transduction. 79 
Conclusions: The Gαs p.F376V mutation causes a previously unrecognized multi-system disorder. 80 
 81 
Introduction 82 
Heterotrimeric G-proteins, comprised of a specific alpha (α) subunit and associated beta (ȕ) and gamma 83 
(Ȗ) subunits, activate a variety of distinct intracellular signaling pathways (1,2). These signaling events 84 
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are normally initiated when the G-protein heterotrimer interacts with the cytoplasmic portion of an 85 
agonist-activated G-protein-coupled receptor (GPCR) (3). Activating mutations in either a GPCR or a 86 
G-protein that increase ligand-independent signaling are the cause of several diseases (4,5).  87 
The α-subunit of the stimulatory G-protein (Gαs), encoded by GNAS exons 1-13, links a large number 88 
of different GPCRs to the adenylyl cyclase/cAMP pathway. Through as-yet unknown mechanisms, Gαs 89 
expression from the paternal GNAS allele is reduced in a tissue-specific manner, such that cells of the 90 
renal proximal tubule, thyroid, pituitary, and several other tissues express Gαs predominantly from the 91 
maternal allele. Consequently inactivating Gαs mutations on the maternal allele, as in 92 
pseudohypoparathyroidism type Ia (PHP1A), lead to a multi-system disorder characterized by 93 
parathyroid hormone (PTH)-resistant hypocalcemia, impaired signaling at the thyrotropin receptor 94 
leading to reduced thyroid hormone production, and several other endocrine and developmental 95 
abnormalities (6). 96 
Somatic gain-of-function mutations in Gαs that occur at either position R201 or R227 (7) are found in 97 
a variety of human cancers and benign endocrine tumors (8). In addition, mosaic expression of Gαs 98 
mutations at residue R201 give rise to the McCune-Albright Syndrome. Depending on the embryonic 99 
stage at which the somatic nucleotide change occurred, these patients present with a combination of 100 
different clinical and laboratory findings that can include gonadotropin-independent precocious puberty 101 
in early infancy that is resistant to treatment with GnRH agonists, hyperthyroidism, café-au-lait spots, 102 
and variable skeletal findings (9,10). R201-Gαs mutations are not transmitted through the germline, 103 
presumably because of early lethality due to excessive cAMP signaling (11). 104 
Previously, two male patients with gonadotropin-independent precocious puberty and PTH-resistant 105 
hypocalcemia were shown to carry an identical Gαs mutation, A366S, which was associated with 106 
agonist-independent activation of some GPCRs, yet hormonal resistance at others (12). Thus, these 107 
patients presented with LH-independent precocious puberty and resistance at the receptors for PTH 108 
(PTH1R) and thyrotropin (TSHR). These discrepant findings were thought to be explained by instability 109 
of the Gαs mutant at body temperature, combined with agonist-independent activation of the lutropin 110 
receptor (LHCGR) because of accelerated release of GDP at the lower temperature of the testes. 111 
We now report two unrelated male patients, who were referred to us with an unexplained combination 112 
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of severe asymptomatic infantile hyponatremia, skeletal and growth plate abnormalities, early-onset 113 
pubertal development and apparent PTH-resistance in the proximal, but not in the distal renal tubules. 114 
The same novel Gαs mutation (p.F376V) was identified in both boys and in vitro studies revealed 115 
GPCR-specific signaling abnormalities, which explained the patients unusual phenotypes, i.e. symptoms 116 
that suggested both gain- and loss-of function.  117 
 118 
Patients and Methods 119 
The parents of both patients have consented to the reported investigations. Two unrelated boys presented 120 
first with unexplained hyponatremia in infancy and subsequently with early-onset gonadotrophin-121 
independent precocious puberty, elevated serum PTH concentrations and unique skeletal abnormalities. 122 
This previously unreported combination of symptoms and laboratory findings was indicative of both 123 
gain- and loss-of-function at different GPCRs that had not been encountered in other Gαs-related 124 
diseases (clinical data are summarized in Table 1, comparative phenotypic information is provided in 125 
Table 2, and detailed patient information are available in the supplementary material). 126 
 127 
DNA sequence analyses  128 
GNAS exons 1-13 underwent direct nucleotide sequence analysis for patients 1 and 2; whole exome 129 
sequencing was furthermore performed for patient 1. To determine the parental origin of the mutation, 130 
a PCR fragment was amplified from both patients and their parents that extends from intron 6 to the γ’-131 
non-coding region telomeric of exon 13, i.e. the exon that comprises the patient`s mutation. The PCR 132 
products from each patient were cloned into a TA cloning vector (Life technologies, Darmstadt, 133 
Germany) and 10 independent colonies underwent nucleotide sequence analysis. 134 
 135 
Construction of G-alpha variants 136 
Wild-type (wt) human Gαs (NM_000516) was cloned into the pcDps expression vector, as described 137 
previously (13); investigated Gαs variants were introduced by standard mutagenesis technique. To 138 
determine if G-protein expression is modified in the presence of tested GPCRs, a luciferase (NanoLuc) 139 
was introduced between amino acids 324 and 325 of the wild-type and mutant Gαs. 140 
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 141 
Determination of WT-Gαs and Gαs-variant expression via luciferase activity 142 
HEK293 cells lacking Gαs (GSG-5 cells) were seeded in white 96-well plates (1.5x104/well). The 143 
following day, cells were co-transfected with the NanoLuc-modified wild-type and mutant Gαs, in 144 
combination with the TSHR, LHCGR, MC4R, PTH1R, V2R, or empty vector using Metafectene® 145 
(Biontex, Munich, Germany) according to manufacturer’s protocol using Opti-MEM without phenol 146 
red. 24h after transfection, 25 µl/well NanoLuc substrate Nano-Glo™ (50 µM) was injected using 147 
Berthold Mithras LB 940. The luciferase activity was measured at 460 nm ± 25nm in triplicates. 148 
 149 
Determination of signaling properties of Gαs-variants  150 
Functional characterization of wt and mutant Gαs was performed using mouse fibroblast 2B2 cells that 151 
lack Gnas exon 2 on both alleles (14) and GSG-5 cells, derived from the human embryonic kidney cell 152 
line (HEK293), which had been engineered by CRISPR-Cas9 to lack Gαs; the latter cells were stably 153 
transfected to express the luciferase-based GloSensorTM cAMP reporter. Cells were seeded in 96-well 154 
plates (1x104/well). Next day the different GPCRs (TSHR, MC4R, PTH1R, LHCGR or V2R) were co-155 
transfected with wt or mutant Gαs at a ratio 1:1 using Metafektene (Biontex, Munich, Germany) for βBβ 156 
cells or Lipofectamine-2000 (Invitrogen Promega) for GSG-5 cells according to the manufacturers’ 157 
protocols. Two days later cAMP accumulation assays were performed at 37°C as previously described 158 
(15). For GSG-5 cells, intracellular cAMP was monitored by treating the cells with luciferin (5 mM) 159 
and measuring changes in luminescence over time at room temperature using a PerkinElmer Envision 160 
plate reader. Basal cAMP was measured for 14 minutes immediately following the addition of luciferin, 161 
and ligand-stimulated cAMP responses were subsequently measured for 88 minutes following the 162 
addition of PTH(1-34) (100 nM). 163 
 164 
Data analysis  165 
All data are given as raw data (mean ± SEM) obtained from four independent experiments performed 166 
in triplicates. Bar graphs and dose-response curves as well as statistical analyses were generated using 167 
GraphPad Prism Version 6.0 (GraphPad Software, San Diego, CA). Data obtained with GSG-5 cells are 168 
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reported as means ± SEM of six independent assays; for each assay, data from replicate wells (twelve 169 
for basal and two for each PTH concentration) were averaged before combining the data to obtain the 170 
mean values for the six independent experiments. 171 
 172 
Structural homology modeling 173 
A structural homology model of Gαs in its inactive conformation was generated to study the interactions 174 
of F376 in the context of the wild-type protein. We compared the inactive model with the already known 175 
active and receptor-bound Gαs conformation (16). In brief, an inactive state structure of Gαs without 176 
the N-terminal helix is already available (PDB entry 1AZT (17)) as well as for the trimeric Gi protein 177 
(PDB entry 1GP2 (18)). To build a completed inactive Gαs model, the available Gαs crystal structure 178 
was superimposed onto the α-subunit of Gi and the N-terminal α1-helix (which has not yet been resolved 179 
for the Gαs structure) and was inserted by substituting the N-terminal helix of Gαi into the incomplete 180 
Gαs structure. The mutant amino acids were then introduced in silico into the chimeric template of wild-181 
type Gαs. The resulting completed heterotrimeric Gαs model was refined by geometry optimization and 182 
energy minimization of the side chains until converging at a termination gradient of 0.2 kcal/mol*Å 183 
with constraint backbone atoms, which were finally released in a second minimization step until 184 
converging at a termination gradient of 0.1 kcal/mol*Å. The Gαs-variants (p.F376V, p.F376Y, and 185 
p.F376M) were introduced into the inactive wild-type Gαs model to unravel the potential local impact 186 
of these side chain variations. All structural modifications were performed using the software SYBYL-187 
X 2.0 (Certara, NJ, US). The AMBER F99 force field was used for energy minimization. Structure 188 
images were produced using the PyMOL Molecular Graphics System, Version 1.5, Schrödinger, LLC. 189 
 190 
Results 191 
A previously unrecognized phenotype in two unrelated patients 192 
Both male patients, 7 and 3.5 years of age at last follow-up, respectively, were born at term after 193 
uneventful pregnancies to unrelated parents with no family history of note. A more detailed patient 194 
description and discussion is provided in the supplemental material.  195 
 196 
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Nephrogenic syndrome of inappropriate anti-diuresis (NSIAD) 197 
Both patients presented in the first few days of life with clinically asymptomatic hyponatremia in the 198 
absence of hyperkalemia, which was detected incidentally when analyzing blood glucose and gases. 199 
Investigations revealed no evidence for defects in mineralocorticoid production (hypoaldosteronism) or 200 
action (i.e. pseudohypoaldosteronism) and both patients were deemed euvolemic. A mutation in 201 
vasopressin receptor 2 (AVPR2; protein name V2R) causing NSIAD was suspected in patient 1 but 202 
excluded by direct nucleotide sequence analysis; treatment with sodium supplementation was started. 203 
In patient 2, hypertension induced by sodium supplements and mineralocorticoids (fludrocortisone) was 204 
treated with amlodipine. Copeptin, a marker of arginine vasopressin (AVP) secretion, also known as 205 
CT-proAVP, was low (<3.6 pmol/l) on four occasions when serum sodium was normal or low, yet urine 206 
osmolality remained persistently elevated (>800 mosm/kg). A tolvaptan (V2R antagonist) challenge 207 
failed to increase urine output and to decrease urine osmolality consistent with NSIAD. Treatment with 208 
sodium alone or with sodium and fludrocortisone were discontinued in both patients at 3 years of age.  209 
 210 
PTH-resistance in the proximal, but not the distal, renal tubules 211 
Both patients had persistently elevated PTH serum concentrations in association with total calcium 212 
concentrations that were within the normal range, and serum phosphate levels that were at the upper end 213 
of the normal range or slightly elevated. 25(OH)D and 1,25(OH)2D concentrations were within the 214 
normal range. Both had a low urinary calcium/creatinine ratio (patient 1: 0.05 mol/mol, patient 2: 0.09 215 
mol/mol) and there was no evidence of nephrocalcinosis. Treatment of patient 1 with calcitriol and of 216 
patient 2 with 1-alpha calcidol at relatively low doses reduced PTH serum concentrations.  217 
 218 
Evidence for increased PTH1R activity in bone and growth plates 219 
Both patients had enlarged and persistently open anterior fontanelles beyond the age of one year, rather 220 
short distal phalanges, and subtle widening of the growth plates, but neither had, until the age of 3 yrs, 221 
clinical or radiographic features of AHO such as brachymetacarpy, and there was no evidence for fibrous 222 
dysplasia. Patient 1 developed severe deformities of the lower limbs and suffered a spontaneous right 223 
tibial fracture at 1.5 years of age, which required surgery [Fig. 1]. At the age of 1.25 years, a skeletal 224 
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survey of patient 2 showed subperiosteal erosions, particularly at the proximal radius, metacarpals and 225 
middle phalanges, and evidence of acro-osteolysis at the distal phalanges of hands and feet.  226 
 227 
Gonadotrophin-independent precocious puberty 228 
Both patients were noted to have symmetrical testicular enlargement and signs of precocious puberty at 229 
about 2 years of age that were associated with accelerated growth and significantly advanced bone age. 230 
Elevated serum testosterone concentrations were noted; yet there was no increase in luteinizing hormone 231 
(LH) and follitropin (FSH) secretion after challenge with gonadotropin-releasing hormone (GnRH), i.e. 232 
findings consistent with gonadotrophin-independent precocious puberty [Tab 1]. Treatment with an 233 
aromatase inhibitor (Anastrozole) and initially cyproterone acetate (anti-androgen) was therefore 234 
commenced in both patients; the latter medication was subsequently substituted by Bicalutamide. Based 235 
on the radiographic findings at follow-up after 5 years of treatment in patient 1 and after 1.5 years in 236 
patient 2, these medications have had no significant effect on bone age advancement. The 237 
gonadotrophin-independent precocious puberty resembles that seen in boys with MAS or testotoxicosis 238 
due to activating LHCGR mutations (19). 239 
 240 
Other findings 241 
In Patient 1, hypothyroidism was suspected because of a single low fT4 concentration (0.75 ng/ml, 242 
reference range: 0.89 – 2.22) with a serum TSH serum concentration in the upper normal range (4.08 243 
mU/l, age related reference range: 0.4 -5.97). Thyroid hormone replacement (25 µg/day) was therefore 244 
started at the age of 1 year. In patient 2, TSH concentrations were normal (1.79 mU/l) at 1.2 yrs (age 245 
related reference range 0.3-4.0 mU/l). 246 
Patient 2 has two small café-au-lait patches, but neither patient has additional cutaneous features 247 
characteristic of MAS and neither had palpable cutaneous ossifications as can be observed in PHP1A. 248 
Both patients have delayed motor development and patient 2 also has significantly delayed expressive 249 
language. There is no evidence for abnormalities in the GHRH/GH/IGF1 axis, as determined by IGF1 250 
measurements. However, an effect of excessive GH production on growth may have been masked by 251 
accelerated bone maturation due to severe precocious puberty [Suppl. Fig. 1]. 252 
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 253 
GNAS nucleotide sequence analyses  254 
Direct nucleotide sequence analysis of GNAS exons 1-13 revealed in both patients an identical 255 
heterozygous missense de novo mutation (c.1126T>G; p.F376V) in exon 13, which was not identified 256 
in the parents. Furthermore, whole exome sequencing of patient 1 provided no obvious additional 257 
candidate variants explaining the clinical and metabolic phenotype. To determine whether the identified 258 
mutation resides on the maternal or the paternal GNAS allele, genomic DNA from both patients was 259 
amplified across an informative SNP in GNAS intron 6 (rs919196) and the c.1126T>G variant; note both 260 
patients are C/T, while both mothers are homozygous for C, and both fathers are homozygous for T. 261 
Allele separation was performed by cloning the PCR products. Nucleotide sequence analysis of ten 262 
independent clones revealed that the GNAS exon 13 mutation always segregated together with the 263 
maternal cytosine for SNP rs919196, thus documenting that the Gαs mutation resides on the maternal 264 
allele. 265 
 266 
Functional characterization of Gαs variants 267 
The complex phenotype exhibited by both patients suggested agonist-independent activation of some 268 
GPCRs, yet hormonal resistance at others. The Gαs-F376V mutant was therefore functionally assessed 269 
in cultured cells by co-expressing wild-type and mutant Gαs with the GPCRs implicated in the different 270 
abnormalities, namely V2R (water reabsorption), LHCGR (gonadotrophic action/puberty), PTH1R 271 
(mineral ion homeostasis, bone metabolism, and growth plate development), TSHR (thyroid function) 272 
or melanocortin-4 receptor (MC4R, weight regulation) [Tab. 2]. 273 
To ensure that expression of the G proteins is not influenced by co-transfected receptors, protein levels 274 
of wt-Gαs and Gαs-F376V were determined by measurement of luciferase activity in the presence of all 275 
tested receptors. Cellular levels of wild-type and mutant Gαs were indistinguishable in the presence of 276 
TSHR, VβR, LHCGR and PTH1R; however, in the presence of MC4R, expression of Gαs-F376V was 277 
slightly increased [Suppl. Fig. 2]. To gain further insights into how specific side chain properties at 278 
position 376 might affect signaling function two additional Gαs variants, p.F376M or p.F376Y were 279 
introduced and functionally characterized.  280 
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In 2B2 cells, basal cAMP levels were indistinguishable when co-expressing either Gαs-F376V or wt-281 
Gαs with the TSHR or MC4R [Fig. 2A,B]. However, when co-expressed with V2R, LHCGR, or PTH1R, 282 
the Gαs-F376V variant revealed increased basal cAMP accumulation that was 1.6-, 1.5- and 2.3-fold, 283 
respectively, higher than that observed with cells co-transfected with wt-Gαs [Fig. 2]. In contrast, 284 
agonist-dependent cAMP accumulation was 40-50% lower for all receptors when co-transfected with 285 
the F376V mutant, as compared with wt-Gαs [Fig. 2-3]. To validate results obtained in the 2B2 cell 286 
system, a second cell system, namely HEK293 cells deficient in Gαs (GSG-5), were used to test the 287 
PTH1R in the presence or absence of PTH(1-34) (20). Co-transfection of GSG-5 cells with Gαs-F376V 288 
and the PTH1R resulted in approximately 2-fold higher rates of basal cAMP accumulation, as compared 289 
to cells co-transfected with wt-Gαs and the PTH1R. However, in comparison to cells expressing wt-Gαs 290 
and the PTH1R, the response to PTH(1-34) was blunted in cells co-transfected with Gαs-F376V and the 291 
PTH1R [Suppl. Fig. 2]. 292 
 293 
Additional F376 variants: Substitution of phenylalanine at position 376 with tyrosine (p.F376Y) 294 
resulted in strongly diminished signaling after agonist stimulation when co-expressed with the different 295 
GPCRs [Fig. 2-3], which was similar to the findings with the Gαs-F376V mutant. In the absence of 296 
agonist, Gαs-F376V revealed similarly enhanced cAMP signaling when coexpressed with V2R, 297 
LHCGR and PTH1R [Fig. 2-3]. In contrast, Gαs-F376Y mutant displayed functional properties similar 298 
to those of the patient`s mutation leading to the conclusion that the additional hydrophilic hydroxyl-299 
group of the tyrosine modifies the essential hydrophobic core interactions observed with phenylalanine 300 
present in wild-type Gαs at this position [Fig. 4].  301 
Surprisingly, the Gαs-F376M substitution revealed more complex signaling properties. For V2R and 302 
LHCGR, ligand-induced signaling was comparable to that observed with wild-type Gαs [Fig. 2-3], but 303 
was reduced for TSHR [Fig. 2-3]. In contrast, maximal signaling response was enhanced for the PTH1R 304 
and the MC4R (1.5- to 2-fold) compared to signaling with wild-type Gαs [Fig. 2-3]. Importantly, 305 
methionine at this position does not lead to a significant increase in basal signaling.  306 
 307 
Insights from structural homology models 308 
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Amino acid F376, located in the C-terminal α5-helix, is highly conserved in the alpha-units of different 309 
G proteins [Suppl. Fig. 3]. In the inactive Gαs conformation, the F376 side chain is embedded into a 310 
hydrophobic/aromatic cage formed by L4γ, M60, H64, Fβ1β, Fβ19 and Mββ1, located in the ȕ1-, ȕβ-, 311 
ȕγ-strands and the N-terminal helix 1 [Fig. 4A1]. These residues rearrange considerably during the 312 
activation process to thereby modulate the GDP/GTP-binding pocket. However, unlike disease caused 313 
by mutations at residue R201 (9,10), R227 or A366 (12), F376 is not immediately proximal to the 314 
nucleotide binding site. Nevertheless, substitution with valine at position 376 (p.F376V) is predicted to 315 
disturb the critical network of hydrophobic interactions and to thus indirectly perturb the catalytic site 316 
environment [Fig. 4A2]. In contrast, substitution with methionine (p.F376M) largely maintains the 317 
essential side chain interactions, which is consistent with the near-normal signaling properties observed 318 
for the Gαs-F376M mutant [Fig. 2-3]. The mutation in our patients, Gαs-F376V, with a shorter and more 319 
branched side chain compared to phenylalanine, most likely leads to a loss of tight hydrophobic 320 
interactions, which then can cause, in comparison to the wild-type protein, modifications in the relative 321 
spatial α5-helix orientation. In addition, the p.F376Y mutant with functional properties similar to that 322 
of the mutation identified in our patients, strongly supports the conclusion that the additional hydrophilic 323 
hydroxyl-group also interrupts the essential hydrophobic core interactions. 324 
 325 
Discussion 326 
We here describe a previously unrecognized congenital human disorder caused by a novel, maternal 327 
Gαs mutation, namely p.F376V, that is characterized by a unique combination of clinical and 328 
laboratory findings, including NSIAD and GnRH-independent precocious puberty. In addition, PTH 329 
was elevated because of resistance in the proximal tubules where Gαs is derived predominantly from 330 
the maternal GNAS allele, thus leading to secondary hyperparathyroidism. However, due to biallelic 331 
Gαs expression in most other tissues, including osteoblasts, bone turnover was found to be increased 332 
leading to skeletal changes reminiscent of hyperparathyroidism, i.e. changes that can be encountered 333 
in PHP1B (21). Furthermore, it appears likely that elevated PTH concentration, combined with 334 
normal paternal Gαs expression in chondrocytes, resulted in growth plate changes reminissent of 335 
rickets similar to those encountered in a few young patients with PHP1B (22). Irrespective of the 336 
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underlying mechanisms, the co-incidental identification of two unrelated patients, who presented with 337 
indistinguishable, unusual combinations of clinical and metabolic features, strongly suggest that the 338 
identified de novo p.F376V mutation on the maternal GNAS allele accounts for this thus far not 339 
described phenotypic profile of the disorder. 340 
A novel feature of both patients was agonist-independent activation of the V2R-regulated pathway 341 
leading to NSIAD with the p.Fγ76V mutation in Gαs. Activation of the VβR which is caused by 342 
constitutively increased signaling has not been described in MAS nor in any other Gαs-related disease 343 
reported to date. The resolution of hyponatremia after early infancy was likely due to adaptive 344 
mechanisms, such as changes in nutrition and self-regulation of thirst-driven fluid intake, comparable 345 
to that encountered in patients with NSIAD due to gain-of-function mutations in AVPR2 (23). However, 346 
excessive free water intake may in the future again lead to hyponatremia. 347 
Gonadotrophin-independent precocious puberty can be caused by mosaic of Gαs mutated at residue 348 
R201, as observed in MAS (10) , or by activating somatic or germline LHCGR mutations (19). In the 349 
latter case, the disorder presents with rapid symmetrical growth of testes associated with premature 350 
testosterone production. This is clinically similar to the findings in our two patients, but distinct from 351 
the frequently, but not always, observed asymmetrical testicular volume encountered with somatic 352 
expression of the abnormal Gαs-R201 alleles (24). 353 
Serum PTH concentrations were elevated, yet serum phosphate concentrations were at the upper end of 354 
normal or slightly elevated, but not reduced. This is consistent with reduced PTH-responsiveness of the 355 
PTH1R/Gαs-F376V complex in the proximal tubule cells where Gαs is expressed predominantly from 356 
the maternal GNAS allele. As a consequence of increased serum PTH concentrations, augmented PTH1R 357 
signaling is predicted to occur when this GPCR is coupled to wt-Gαs derived from the paternal allele, 358 
i.e. in tissues with biallelic Gαs expression. The urinary calcium-to-creatinine ratio was low in both 359 
patients indicating that calcium reabsorption is fully functional in the distal tubules, where Gαs is 360 
expressed from both parental alleles. Thus, either PTH can stimulate efficiently the complex comprising 361 
the PTH1R and paternal wt-Gαs, as is observed in PHP1B and PHP1A, and/or ligand-independent 362 
calcium reabsorption occurs due to the complex between the PTH1R and the maternal Gαs-F376V 363 
mutant. 364 
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The skeletal changes leading to bowing of weight-bearing bones as well as the subperiosteal erosions 365 
and acro-osteolysis, particularly of the distal phalanges [Fig. 1], were in keeping with enhanced 366 
activation of the PTH1R expressed in osteoblasts. These changes might be caused by agonist-367 
independent signaling mediated by complexes formed between the unoccupied PTH1R and Gαs-F376V 368 
in osteoblasts which could lead to increased rates of bone turnover and resorption. However, the agonist-369 
independent effects on osteoblasts, and chondrocytes as outlined above, could be augmented also by 370 
elevated serum PTH concentrations and thus sustained activation of the PTH1R coupled to wt-Gαs, 371 
which is reminiscent of secondary hyperparathyroidism in children with PHP1B or chronic kidney 372 
disease (21,22).  373 
 374 
To better understand the mechanisms responsible for this previously unreported human disorder, we co-375 
expressed Gαs variants with a sub-set of GPCRs that are expressed in tissues, which are known to be 376 
associated with the symptoms observed in our patients [Tab. 2]. In fact, ligand-independent signaling 377 
was induced when the Gαs-F376V mutant was co-expressed with the V2R, PTH1R and LHCGR in 378 
concordance with the clinical symptoms of the two patients, but not with the TSHR and MC4R [Fig. 2-379 
3]. Also consistent with in vivo evidence for PTH-resistance in proximal tubules our in vitro experiments 380 
revealed a blunted response to PTH(1-34) when the PTH1R was co-expressed with the Gαs-F376V 381 
mutant [Fig. 3 and Suppl. Fig. 3]. The p.F376V mutation resides in both patients on the maternal allele, 382 
which contributes in some tissues, such as the proximal renal tubules, most or all Gαs protein. In vitro, 383 
the response to PTH was blunted at the PTH1R in the presence of the Gαs mutant, which is likely 384 
responsible for the PTH elevation caused by PTH1R resistance in this portion of the kidney. It thus 385 
appears plausible that the presence of the p.F376V mutation on the paternal GNAS allele could lead only 386 
to NSIAD and gonadotrophin-independent precocious puberty without PTH resistance. The fact that the 387 
maternal p.F376V mutation facilitates ligand-independent cAMP formation in a receptor-specific 388 
manner is consistent with the clinical findings observed in both boys. Three different mechanisms are 389 
likely to explain the unusual combination of findings in our patients, which include features of both 390 
loss- and gain-of-function of Gαs: (i) loss-of-function effects that are caused by impaired activity of the 391 
Gαs mutant and thus hormonal resistance in those target tissues that rely predominantly or exclusively 392 
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on maternal Gαs expression, (ii) GPCR-dependent gain-of-function effects that are agonist-independent, 393 
and (iii) effects that are caused by the elevated PTH concentrations and activation of the PTH1R when 394 
coupled to the wt-Gαs transcribed from the paternal GNAS allele.  395 
 396 
At the protein structural level phenylalanine 376 is located near the C-terminus of the Gαs α5-helix and 397 
a phenylalanine at this position is highly conserved among all G-protein subtypes [Suppl. Fig. 4]. In the 398 
inactive conformation, its aromatic side chain is embedded into a hydrophobic core that is formed by 399 
side chains projecting from several different portions of the Gαs scaffold [Fig. 4A1]. This localization 400 
enables F376 to act as a key transducer of the conformational forces that propagate from the C-terminal 401 
portion of the α5-helix as it engages an activated receptor (25,26) [Fig. 4B] to the interior components 402 
of the G-protein that directly participate in the GDP/GTP exchange mechanism (27). A valine mutation 403 
at F376 likely causes a marked perturbation of the hydrophobic core configuration and consequently 404 
α5-helix changes that differ from those of the wild-type protein [Fig. 4B1]. This hypothesis for Gαs is 405 
supported by in vitro studies at Gi, where mutations at the corresponding phenylalanine lead to rotation 406 
of the α5-helix (28). Moreover, in vitro studies at the corresponding phenylalanines of Gαt (29) or Gαi 407 
(30) revealed constitutive G-protein activation with respect to an increased GDP/GTP exchange, but 408 
they are (partially) resistant to stimulation by agonist-occupied GPCRs. Amino acid F376 in Gαs 409 
corresponds to F341 in Gα11 where the p.F341L mutation causes autosomal dominant hypocalcemia 410 
(31).  411 
Our experimental data indicate that the p.F376V mutation, combined with the proposed spatial 412 
displacement of the α5-helix, decreases ligand-induced down-stream signaling at the investigated 413 
receptor/ligand complexes [Fig. 2,3]. As already known from a crystallized GPCR/Gs complex (16) 414 
[Fig. 4B], Gαs undergoes major global and local structural movements during activation (25,27,28,32). 415 
This general finding has recently been confirmed at the structural level also for GPCRs complexed with 416 
Gi or Go, as elucidated by cryo-electron microscopy (33-35). In the active state, F376 within the 417 
GPCR/Gαs complex (16) is located spatially close to the intracellular loop 2 (Il2) of the receptors, but 418 
a direct contact was not observed in these GPCR/G-protein complexes without bound nucleotides. 419 
Therefore it can only be speculated that F376 may play a crucial role for a potential pre-coupled state, 420 
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the transition between the inactive and fully-active state, or for dissociation of the G-protein from the 421 
GPCRs. In addition, our findings based on side chain variations at position 376 support two hypotheses: 422 
(1) The receptors are different in their fine-tuned interaction process with Gαs, which would be in 423 
accordance with the differences in basal activity observed for the tested GPCRs in complex with the 424 
Gαs-F376V mutant. (2) Maintenance of the hydrophobic side-chain at this position is essential to 425 
facilitate signaling and a methionine can maintain these properties in contrast to a valine. 426 
 427 
In summary, the in vivo and in vitro findings suggest that NSIAD is caused by a recurrent maternal Gαs 428 
mutation (p.F376V), which also leads to precocious puberty and skeletal dysplasia [Tab. 2]. It can 429 
therefore be expected that other more common diseases, such as precocious puberty or skeletal dysplasia 430 
or NSIAD of unknown origin, can be caused by Gαs mutations similar to p.F376V, if these reside on 431 
the paternal GNAS allele thus enhancing GPCR-independent signaling. The knowledge gained from 432 
unique ligand-independent and ligand-dependent consequences caused by this Gαs variant will be 433 
helpful in the future development of targeted therapies, and for the clinical management of these patients, 434 
for example, restricted fluid intake in view of the predisposition to hyponatremia. 435 
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Table and Figure legends 578 
 579 
Table 1: Clinical and metabolic findings in the two patients. Clinical and biochemical findings in the 580 
patients with p.F376V compared to patients with pseudohypoparathyroidism and precocious puberty 581 
(p.A366S) caused by protein instability (12) or found in McCune Albright Syndrome (p.R201H) (10). 582 
Characteristic findings of the three different diseases are highlighted. “+” present, “-“ not present, “+/- 583 
“ unilateral testes enlargement 584 
 585 
Table 2: Review of inherited human diseases caused by impaired GPCR function. Human diseases 586 
caused by variants of GPCR or Gαs of either loss- or gain-of-function consequences including the novel 587 
phenotypes caused by variant p.F376V studied in this report. Receptor +/Gαs + = gain-of-function 588 
variants, Receptor -/Receptor - = Loss-of-function variants 589 
 590 
Figure 1: Radiographic studies of skeletal features in the patients. Radiographs of patient 1 showing 591 
the skeletal abnormalities such as antecurvatura of the left distal tibia, bowing of both upper legs, 592 
enlargement of the metaphyses. A) Radiographic study of patient 1, at 1 year 8 months and 7 years. B) 593 
Radiographic study of patient 2 at 1 year and 3 months.  594 
 595 
Figure 2: Functional characterization of wt Gαs and variants co-expressed with several different 596 
GPCRs. 2B2 cells were co-transfected with GPCRs, and either wild-type or mutant Gαs, as indicated. 597 
After two days, cAMP accumulation was determined in the absence or presence of maximal 598 
concentration of indicated ligands by alpha screen technology. Results of four independent experiments 599 
performed in triplicated were shown as mean ± SEM. Statistical analysis was performed with one-way 600 
ANOVA with Kruskal-Wallis test, indicated receptors + Gαs were tested against receptors in the 601 
presence of different Gαs variants; * p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. 602 
 603 
Figure 3: Functional characterization of wt Gαs and variants co-expressed with different GPCRs. 604 
2B2 cells were co-transfected with GPCRs, and wild-type or mutant Gαs, as indicated. After two days, 605 
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cAMP accumulation was determined in the presence of decadic increasing concentration of indicated 606 
ligands by alpha screen technology. Results of four independent experiments performed in triplicates 607 
were shown as mean ± SEM. 608 
 609 
Figure 4: Phenylalanine 376 in different Gαs conformations and activity states. A-A1) In the inactive 610 
state conformation of the heterotrimeric Gαs amino acid F376 is cage-like embedded by several 611 
hydrophobic and/or aromatic amino acids (shown as green sticks). F376 is not directly located at the 612 
GDP/GTP (shown as orange spheres) binding pocket unlike known pathogenic Gαs mutations, e.g. 613 
residues A366, R201 or Q227 (7) (magenta sticks). A2). Mutational variants such as p.F376V, p.F376Y 614 
and p.F376M lead to specific changes in the tight hydrophobic/aromatic environment at position 376. 615 
Methionine is aliphatic in contrast to phenylalanine, but is hydrophobic and interacts with aromatic ring 616 
systems. Valine is characterized by a shorter and more branched side chain compared to phenylalanine. 617 
The patient mutant F376V therefore most likely leads to a loss of the tight interactions, which finally 618 
can cause structural modifications in the relative spatial α5-helix orientation compared to wild-type. B) 619 
From the crystal structure Gαs/ȕ-2AR complex (PDB entry 3SN6 (16)) it is known that the Gαs-protein 620 
undergoes structural re-organization during interaction with the receptor, e.g. a global movement of the 621 
helical domain (arrow), enabled by ligand-induced conformational changes in the receptor. B1) The 622 
superimposition between the active and the inactive Gs crystal structure shows that F376 changes the 623 
spatial localization during G-protein activation related to local movements of the C-terminal α5-helix. 624 
